Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Pretreatment Patient Characteristics Associated with Achieving Bone Marrow Minimal Residual Disease-Free Status with Frontline Fludarabine, Cyclosphosphamide, Rituximab (FCR) Chemoimmunotherapy for CLL,

William G. Wierda, MD, PhD, Susan O'Brien, MD, Alessandra Ferrajoli, MD, Charles Asa Koller, MD, Jan A. Burger, MD, PhD, Stefan Faderl, MD, Guillermo Garcia-Manero, Tapan Kadia, Susan Lerner, MS, BA, Michael J Keating, MD

Blood (2011) 118 (21): 3902.

https://doi.org/10.1182/blood.V118.21.3902.3902

Published: 2011

Journal Articles

Long Term Followup and Patterns of Failure in Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Treated On Studies Combining a Hypomethylating Agent and the Histone Deacetylase Inhibitor (HDACi) Valproic Acid.

Tapan Kadia, MD, Zeev Estrov, MD, Farhad Ravandi, M.D., Charles Asa Koller, MD, Gautam Borthakur, MD, Elias Jabbour, MD, Stefan Faderl, MD, Sherry Pierce, RN, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2009) 114 (22): 2074.

https://doi.org/10.1182/blood.V114.22.2074.2074

Published: 2009

Journal Articles

Combination of the hyperCVAD Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Meyloid Leukemia (CML-LB)

Elias Jabbour, Susan O’Brien, Deborah A. Thomas, Stefan Faderl, MD, Charles Asa Koller, MD, Samuel Dara, Rebecca Garris, Jorge Cortes, MD, Hagop M Kantarjian, Farhad Ravandi

Blood (2008) 112 (11): 2919.

https://doi.org/10.1182/blood.V112.11.2919.2919

Published: 2008

Journal Articles

Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Jeffrey L. Jorgensen, MD, PhD, Stefan Faderl, MD, Jorge Cortes, MD, Francis Giles, MD, Guillermo Garcia-Manero, MD, William Wierda, MD, PhD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Charles Asa Koller, MD, Miloslav Beran, MD, PhD, Steven M. Kornblau, MD, PhD, Michael Andreeff, MD, PhD, Dan Jones, MD, PhD, Susan O’Brien, MD

Blood (2006) 108 (11): 1861.

https://doi.org/10.1182/blood.V108.11.1861.1861

Published: 2006

Journal Articles

Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).

Ricardo H. Alvarez, MD, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, Farhad Ravandi-Kashani, MD, Srdan Verstovsek, MD, Francis Giles, MD, Susan O’Brien, MD, Charles Asa Koller, MD, Stefan Faderl, MD, Deborah Thomas, MD, John J. Wright, MD, Jorge Cortes, MD

Blood (2006) 108 (11): 1999.

https://doi.org/10.1182/blood.V108.11.1999.1999

Published: 2006

Journal Articles

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Regimen for Heavily Treated Patients with CLL.

William G. Wierda, MD, PhD, Susan O’Brien, MD, Stefan Faderl, MD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Jorge Cortes, MD, Francis Giles, MD, Michael Andreeff, MD, PhD, Charles Asa Koller, MD, Susan Lerner, MS, RHIA, Hagop M. Kantarjian, MD, Michael J. Keating, MBBS

Blood (2006) 108 (11): 31.

https://doi.org/10.1182/blood.V108.11.31.31

Published: 2006

Journal Articles

Immune Modulation of Minimal Residual Disease (MRD) in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CP): A Randomized Trial of Frontline High-Dose (HS) Imatinib Mesylate (IM) with or without Pegylated-Interferon (PEG-IFN) and GM-CSF.

Alfonso Quintas-Cardama, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Susan O’Brien, MD, Srdan Verstovsek, MD, Charles Asa Koller, MD, Odeal Pate, Jorge Cortes, MD

Blood (2006) 108 (11): 2207.

https://doi.org/10.1182/blood.V108.11.2207.2207

Published: 2006

Journal Articles

The Effect of Interleukin-11 (Oprelvekin, Neumega®) on Thrombocytopenia Associated with Tyrosine Kinase Inhibitors (TKI) in Patients with Chronic Myeloid Leukemia (CML).

Ahmed M. Aribi, MD, Hagop Kantarjian, MD, Patricia Ault, MD, Charles Asa Koller, MD, Deborah Thomas, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Jorge Cortes, MD

Blood (2006) 108 (11): 2148.

https://doi.org/10.1182/blood.V108.11.2148.2148

Published: 2006

Journal Articles

Sokal and Hasford Scores Are Able To Predict Cytogenetic Response and Survival in CML Patients Who Failed Prior Therapy and Are Receiving Salvage Therapy with Imatinib or Other Tyrosine Kinase Inhibitors.

Constantine S. Tam, MBBS, Hagop M. Kantarjian, MD, Jenny Shan, PhD, William G. Wierda, MD, PhD, Alessandra Ferrajoli, MD, Charles Asa Koller, MD, Jorge Cortes, MD

Blood (2006) 108 (11): 2157.

https://doi.org/10.1182/blood.V108.11.2157.2157

Published: 2006

Journal Articles

Thrombopoietin as an Independent Prognostic Marker in Chronic Lymphocytic Leukemia.

Charles Asa Koller, MD, B. Nebiyou Bekele, PhD, Xian Zhou, PhD, Charles Park, BS, Zeef Estrove, MD, Susan O’Brien, MD, Michael Keating, MD, Iman Jilani, PhD, Francis J. Giles, MD, Hagop M. Kantarjian, MD, Maher Albitar, MD

Blood (2004) 104 (11): 1905.

https://doi.org/10.1182/blood.V104.11.1905.1905

Published: 2004

NARROW

Pretreatment Patient Characteristics Associated with Achieving Bone Marrow Minimal Residual Disease-Free Status with Frontline Fludarabine, Cyclosphosphamide, Rituximab (FCR) Chemoimmunotherapy for CLL,

Long Term Followup and Patterns of Failure in Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Treated On Studies Combining a Hypomethylating Agent and the Histone Deacetylase Inhibitor (HDACi) Valproic Acid.

Combination of the hyperCVAD Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Meyloid Leukemia (CML-LB)

Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Regimen for Heavily Treated Patients with CLL.

Immune Modulation of Minimal Residual Disease (MRD) in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CP): A Randomized Trial of Frontline High-Dose (HS) Imatinib Mesylate (IM) with or without Pegylated-Interferon (PEG-IFN) and GM-CSF.

The Effect of Interleukin-11 (Oprelvekin, Neumega®) on Thrombocytopenia Associated with Tyrosine Kinase Inhibitors (TKI) in Patients with Chronic Myeloid Leukemia (CML).

Sokal and Hasford Scores Are Able To Predict Cytogenetic Response and Survival in CML Patients Who Failed Prior Therapy and Are Receiving Salvage Therapy with Imatinib or Other Tyrosine Kinase Inhibitors.

Thrombopoietin as an Independent Prognostic Marker in Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only